IL2 and renal cell carcinoma: Furthermore, the combination of YM155 and IL-2 demonstrated an additive antitumor effect on both orthotopic renal and metastatic lung tumors in a RENCA mouse model of RCC and induced the additional downregulation of peripheral myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) in vivo.